JP2005170846A - Hyaluronic acid production promoter - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To obtain a safe hyaluronic acid production promoter affecting human health little, and usable in preventing skin aging or treating diseases associated with the abnormal decomposition of hyaluronic acid by promoting hyaluronic acid production ability by cells. <P>SOLUTION: This hyaluronic acid production promoter is characterized by comprising a 3-methylcyclopentadecanone[ preferably (R)-(-)-3-methylcyclopentadecanone ]. <P>COPYRIGHT: (C)2005,JPO&NCIPI

Description

  The present invention relates to a hyaluronic acid production promoter that promotes hyaluronic acid production in cultured cells or living bodies, and also relates to a hyaluronic acid production promoter that can be added to cosmetics, pharmaceuticals, etc. to enhance the hyaluronic acid production ability of the skin.

  Hyaluronic acid retains moisture in the interstitial space, retains cells based on the formation of a jelly-like matrix in the tissue, maintains tissue lubricity and flexibility, resists external forces such as mechanical failure, and And has many functions such as prevention of bacterial infection (see Non-Patent Document 1).

  For example, hyaluronic acid in the skin decreases with age, and as a result, it is said that it causes aging such as fine wrinkles and bulkiness.

  Many cosmetics containing collagen and hyaluronic acid have been proposed as an ameliorating agent for such aging skin, but it only improves the moisturizing effect on the surface and does not essentially improve aging skin. Absent. In addition, vitamins and herbal medicines are used as skin cell activators, but the treatment of aging skin has not been achieved.

  Further, hyaluronic acid in the joint fluid covers the surface of the articular cartilage and is useful for smooth operation of the joint function. The concentration of hyaluronic acid in normal human joint fluid is about 2.3 mg / mL, but in the case of rheumatoid arthritis, the concentration of hyaluronic acid in joint fluid decreases to about 1.2 mg / mL and at the same time the viscosity of joint fluid (See non-patent document 2).

  In addition, it is known that hyaluronic acid content decreases in pyogenic arthritis and gouty arthritis as in the case of rheumatoid arthritis (see Non-Patent Document 3).

  In the above diseases, it is conceivable to increase the amount of hyaluronic acid in the joint fluid in order to improve the lubrication function, cover and protect the articular cartilage, suppress pain, and improve the properties of the pathological joint fluid. For example, the above improvement has been observed when a joint injection therapy with sodium hyaluronate is performed on a patient with rheumatoid arthritis (see Non-Patent Document 4).

  Similarly, in the case of traumatic arthritis, osteoarthritis and osteoarthritis, the above-mentioned improvement effect has been reported by joint injection therapy with hyaluronic acid (see Non-Patent Document 5).

  However, treatment of the above diseases is long-lasting and requires a doctor's prescription. Therefore, an ointment or gel containing a hyaluronic acid production promoter that can be easily treated in daily life has been desired.

  In the healing process after burn injury, hyaluronic acid is known to increase markedly in the granulation during the period from the beginning of the granulation tissue growing from below the necrotic tissue until the entire tissue is replaced with the granulation tissue. (See Non-Patent Document 6), hyaluronic acid production promoters are also expected as an early treatment for burns.

  Drugs that promote the production of hyaluronic acid in human cells include cytokines such as insulin-like growth factor-1, epidermal growth factor (see Non-Patent Document 7) and interleukin-1 (see Non-Patent Document 8), or phorbol esters ( Non-patent document 9) is known, but none of them can be used with confidence as cosmetics, bathing agents or pharmaceuticals.

“BIO INDUSTRY”, 1991, Vol. 8, p. 346 “Arthritis Rheumatism”, 1967, Vol. 10, p. 357 “Connective tissue”, 1984, Kanehara Publishing, p. 481 “Inflammation”, 1991, Vol. 11, p. 16 “Connective tissues and diseases”, 1980, Kodansha, p. 246 “Connective tissues and diseases”, 1980, Kodansha, p. 153 “Biochimica Biophysica Acta”, 1989, Vol. 1014, p. 305 “Journal of Japan Society of Obstetrics and Gynecology”, 1989, Volume 41, p. 1943 “Experimental Cell Research”, 1983, 148, p. 377

  Therefore, the object of the present invention is to promote the hyaluronic acid production ability by cells, and thus can be used for the prevention of skin aging or the treatment of diseases accompanied by abnormal decomposition of hyaluronic acid, and it is safe and has little influence on the human body. It is in providing a hyaluronic acid production promoter.

  The above object is achieved by a hyaluronic acid production promoter characterized by containing 3-methylcyclopentadecanone, particularly preferably (R)-(−)-3-methylcyclopentadecanone.

  When the hyaluronic acid production promoter of the present invention is added to a human dermal fibroblast culture system, hyaluronic acid production is promoted (see Test Example-1 described later). Therefore, the hyaluronic acid production promoter of the present invention acts on fibroblasts and can promote hyaluronic acid production in connective tissues such as skin, which are pathologically or physiologically reduced.

  Hereinafter, the configuration of the present invention will be described in detail.

  3-methylcyclopentadecanone used in the present invention is a known compound. It is the main aroma component of natural musk and is contained in an amount of 0.5 to 2.0%. Discovered by Walbaum in 1906. In 3-methylcyclopentadecanone, (R)-(−)-3-methylcyclopentadecanone and (S)-(+)-3-methylcyclopentadecanone exist as optically active substances. The natural type is (R)-(−)-3-methylcyclopentadecanone. In the present invention, (R)-(−)-3-methylcyclopentadecanone is preferably used.

The method for producing 3-methylcyclopentadecanone used in the present invention is not particularly limited. It may be isolated from a natural product, and can be obtained by synthesis by a cyclization reaction, ring expansion reaction, or the like, or an optically active substance resolution method.

  Since 3-methylcyclopentadecanone and (R)-(−)-3-methylcyclopentadecanone used in the present invention are small molecules, they pass through the epidermal layer and the basement membrane when applied to the skin. However, it can reach the dermis layer (connective tissue) where fibroblasts are present, which is advantageous for promoting the ability of fibroblasts to produce hyaluronic acid.

  The hyaluronic acid production promoter of the present invention can be applied to cultured cells or living cells by itself to promote hyaluronic acid production. However, the hyaluronic acid production promoter of the present invention may be used in cosmetics, pharmaceutical compositions, etc. good.

  The form of the hyaluronic acid production promoter of the present invention and the composition containing the hyaluronic acid production promoter may be any of a liquid, a solid or a semi-solid, preferably an ointment, gel, cream, spray, patch, lotion, pack. , Emulsions, powders, toiletries, foaming agents, perfumes and bathing agents.

In addition to the above, the hyaluronic acid production promoter of the present invention includes tar pigments, colored pigments such as iron oxide, preservatives such as paraben and phenoxyethanol, silicon such as dimethylpolysiloxane, methylphenylpolysiloxane, and cyclic silicon. Oils, hydrocarbons such as paraffin and petrolatum, olive squalane, rice squalane, rice germ oil, jojoba oil, sunflower oil, safflower oil, olive oil, macadamia nut oil, sunflower oil and other vegetable oils, beeswax, moscow, carnauba wax and other waxes , Octyldodecyl myristate, cetyl palmitate, isostearyl isostearate, isopropyl myristate, etc., lower alcohols such as ethanol, higher alcohols such as cetanol, behenyl alcohol, stearyl alcohol, long-chain branched aliphatic alcohols, etc. Sterols and derivatives such as cholesterol, phytosterol, branched fatty acid cholesterol ester, macadamia nut fatty acid phytosteryl ester, processing oils such as hardened oil, stearic acid, myristic acid, isostearic acid, oleic acid, isoform long chain fatty acid, anteisoform length Higher fatty acids such as chain fatty acids, terpenes such as limonene and hydrogenated bisabolol, triglycerides such as tricapryl / glyceryl caprate, glyceryl 2-ethylhexanoate, triiso type long chain fatty acid glyceryl, glyceryl tripalmitate, sodium cetyl sulfate, N -Anionic surfactant such as stearoyl-L-glutamate, polyoxyethylene alkyl ether, polyoxyethylene fatty acid ester, polyoxyethylene polyhydric alcohol fatty acid ester , Polyoxyethylene hydrogenated castor oil, polyhydric alcohol fatty acid ester, polyglycerin fatty acid ester, modified silicone, nonionic surfactant such as sucrose ester, cationic surfactant such as tetraalkylammonium salt, betaine type, sulfone Amphoteric surfactants such as betaine type and sulfoamino acid type, natural surfactants such as lecithin, lysophosphatidylcholine, ceramide, cerebroside, pigments such as titanium oxide and zinc oxide, antioxidants such as dibutylhydroxytoluene, Inorganic salts such as sodium chloride, magnesium chloride, sodium sulfate, potassium nitrate, sodium sulfate, sodium metasilicate, calcium chloride, sodium citrate, potassium acetate, sodium oxalate, sodium aspartate, sodium lactate, dichloroacetic acid, mevalonic acid, Organic acids such as glycyrrhizic acid and salts thereof, ethanolamine hydrochloride, ammonium nitrate, arginine hydrochloride, diisopropylamine salts, organic amines such as urea and decarboxycarnosine and salts thereof, chelating agents such as edetic acid, xanthan gum, carboxyvinyl polymer, Carrageenan, pectin, alkyl-modified carboxyvinyl polymer, thickeners such as agar, neutralizing agents such as potassium hydroxide, diisopropanolamine, triethanolamine, UV absorbers such as hydroxymethoxybenzophenone sulfonate, dipropylene glycol, 1,3-butylene glycol, glycerin, propylene glycol, sorbitol, malbitol, diglycerin, raffinose and other polyhydric alcohols, various amino acids, ascorbic acid, biotin, tocophero Vitamins and ascorbic acid sulfuric acid ester salts such as Le,
Vitamin derivatives such as ascorbic acid phosphate salt and tocopherol nicotinate can be appropriately blended within the scope of achieving the object of the present invention.

  Furthermore, N-methyl-L-serine, dermal hyaluronic acid production promoters such as yeast extract, hyaluronic acid degradation inhibitors such as poppy mushroom extract, Kurita mushroom extract, Kurokawa extract, mockin extract, asenyaku extract, clove extract, etc., diisopropyl Keratinization accelerators such as amine dichloroacetic acid, niacin, mevalonic acid, hot spring water, sodium metasilicate, barrier enhancers such as β-hydroxy-γ-aminobutyric acid, mevalonic acid, hyaluronic acid, glucosamine, glucuronic acid, glycerol, urea By adding a moisturizing agent such as polyhydric alcohol, the effect of preventing rough skin and wrinkles can be further enhanced.

  The content of 3-methylcyclopentadecanone and (R)-(−)-3-methylcyclopentadecanone used in the present invention in the hyaluronic acid production accelerator varies depending on the form and cannot be defined unconditionally. However, 0.0000001 to 0.01% (W / W) is preferable, and more preferably 0.00001 to 0.001% (W / W), where the entire applied composition is 100% (W / W). . However, in the case of a thing diluted at the time of use like a bath agent, the content can be further increased.

  When hyaluronic acid is produced in cultured cells, in the case of 3-methylcyclopentadecanone and (R)-(−)-3-methylcyclopentadecanone, 0.0000001 to 0.001 in the cell culture solution. It is preferable to contain 001% (W / W), more preferably 0.000001 to 0.0001% (W / W).

  Prior to the examples, test examples showing the effects of the present invention will be described. In addition, the preparation method and measurement method of the reagent used for each test are as follows.

(A) Preparation method of MEM medium Minimum Essential Medium (manufactured by Dainippon Pharmaceutical Co., Ltd., 10-101) 10.6 g as the final concentration of 1% (V / V) Non Essential
Amino Acid (Dainippon Pharmaceutical Co., Ltd., 16-810), 1 mmol / L sodium pyruvate (Dainippon Pharmaceutical Co., Ltd., 16-820), 1.2% (W / V) sodium bicarbonate and distilled water were added. After 1 L, carbon dioxide was blown to adjust the pH to about 7 (hereinafter abbreviated as MEM medium).

(B) Inactivation of fetal bovine serum (FBS) FBS (Irvine Scientific) was heat-treated at 56 ° C for 30 minutes.

(C) Pronase solution 200 μg / mL Pronase (manufactured by Calbiochem-Behring Corporation, derived from Streptomyces griseus), 0.15 mol / L sodium chloride and 0.02% sodium azide-containing 0.5 mol / L Tris-HCl buffer (pH 8) 0.0).

(Test Example 1) Hyaluronic acid production promoting action Test compound: (R)-(−)-3-methylcyclopentadecanone

2. Test method:
Cell culture Normal human fibroblast cell line [Detroit 551 strain (ATCC CCL 110)] 0.6
× 10 ⁵ seeds / well seeded in a 24-well plate and 95% (V / V) air-5% (V / V) carbonic acid in MEM medium with 10% (V / V) inactivated FBS The culture was allowed to stand at 37 ° C. for 3 days in a gas atmosphere, and further cultured in a serum-free MEM medium for 1 day. Subsequently, after culturing for 3 days in the medium to which the sample was added, the culture supernatant was recovered and the amount of hyaluronic acid in the supernatant was determined.

-Measurement of hyaluronic acid production amount Pronase solution 0.07mL was added to culture supernatant 0.63mL, and after leaving still at 37 degreeC for 18 hours, it heat-processed at 100 degreeC for 10 minutes, and inactivated pronase. Next, the amount of hyaluronic acid was measured from 0.01 mL of the reaction solution using a hyaluronic acid plate “Chugai” (manufactured by Chugai Diagnostics Science Co., Ltd.) according to the attached instructions. In addition, the sample addition tested in each group n = 3, and the result used the average value of each.

3. Test results:
The amount of hyaluronic acid produced in the culture supernatant when various concentrations of (R)-(−)-3-methylcyclopentadecanone were added was measured (Table 1).
As a result, it was found that the addition of (R)-(−)-3-methylcyclopentadecanone increases the amount of hyaluronic acid produced by the Detroit 551 strain.

  Examples of the present invention are given below. In addition, the value in a table | surface shows the mass%.

Examples 1-4 (cream)
A cream was prepared with the composition shown below.

Preparation method: Component (A) was uniformly mixed and dissolved at 80 ° C., and then component (B) was mixed and dissolved therein (mixed solution I).
Separately, component (D) was uniformly mixed and dissolved at 80 ° C., and then component (C) was mixed and dissolved therein (mixed solution II).
Next, the liquid mixture II was gradually added to the liquid mixture I, and it cooled to 30 degreeC, stirring sufficiently, and the cream was obtained.

Examples 5-8 (Lotion)
A lotion was prepared with the composition shown below.

Preparation method: Each component was mixed and dissolved to prepare a lotion.

Examples 9 to 10 (baths)

Preparation method: Each component was mixed to prepare a bath agent. In addition, this bath agent is diluted about 3000 times at the time of use.

Examples 11-14 (ointment)

Preparation method: Each component of the above (B) is mixed while heating to 80 ° C in a hot water bath, and this is gradually added to the mixture of each component of (A) heated to 80 ° C while stirring. It was.
Next, after vigorously stirring (2500 rpm) for 2.5 minutes with a homogenizer (manufactured by Tokuyukika Kogyou), each component was sufficiently emulsified and dispersed, and then gradually cooled with stirring to obtain an ointment.

Examples 15-18 (gel)

Preparation method: (A) was swollen with a part of water (D), component (C) was dissolved with the remaining water (D), and then both were uniformly mixed (mixed solution I).
Component (B) was mixed and dissolved uniformly (mixture II).
The mixture I was added to the mixture I and dispersed therein to obtain a gel.

Examples 19-22 (hair tonic)

Preparation method: After dissolving the fragrance with the fragrance solubilizer, the mixture was dissolved in ethanol while stirring at room temperature, and the component (B) was sequentially added and dissolved (mixed solution I).
The component (C) was dissolved and added to the mixture I with stirring to make it uniform, followed by filtration to obtain a hair tonic.

Claims (2)

A hyaluronic acid production promoter comprising 3-methylcyclopentadecanone. A hyaluronic acid production promoter characterized by containing (R)-(−)-3-methylcyclopentadecanone.